Harvard Business Review recently published a piece highlighting that a large reason why health care outcomes in the United States appear to underperform compared with international peers is because we are investing too much in low-value services, which have little to no clinical benefit relative to cost.

“There is an abundance of high-quality comparative effectiveness data for pharmaceuticals, largely because of the drug approval process, but there’s less data on the value of other expensive investments into health, such as doctor visits and hospitalizations,” wrote the authors. But it’s not just a lack of information, as the piece makes clear. There are misaligned incentives and insufficient education. Addressing those root causes are critical in shifting the investment of precious health-system dollars from low-value services to services that have profound and well-understood health benefits.

The article is available at the Harvard Business Review, and we encourage you to share your thoughts using the #GoingBelowTheSurface hashtag on Twitter.